Bernstein raised the firm’s price target on Dyne Therapeutics (DYN) to $23 from $21 and keeps a Market Perform rating on the shares. The firm notes the company announced positive data from the registrational expansion cohort of DYN-251, its exon 51 skipper for Duchenne muscular dystrophy. Bernstein found the data overall quite compelling and believes it is derisking for the platform itself, accelerated approval of this drug, and the company’s financing needs.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics Amends Loan Agreement for $50 Million
- Dyne Therapeutics offers to sell $300M in common stock
- Dyne Therapeutics price target raised to $60 from $46 at H.C. Wainwright
- Dyne Therapeutics Reports Positive Phase 1/2 Trial Results
- Dyne Therapeutics reports ‘positive’ results from Phase 1/2 DELIVER trial